Burdensome Research Procedures in Trials: Why Less Is More
- PMID: 28376159
- PMCID: PMC5756064
- DOI: 10.1093/jnci/djw315
Burdensome Research Procedures in Trials: Why Less Is More
Abstract
A large volume of trials involve invasive, nontherapeutic research procedures, like organ biopsy or sham surgeries, that can pose risks comparable with the experimental treatment itself but that have no direct benefit for volunteers. Though such procedures can enhance the value of clinical investigations, recent studies suggest that many studies involving invasive, nontherapeutic research procedures are not well planned and reported; some studies suggest that their results are often not utilized in the planning of new investigations. This commentary offers recommendations for how investigators, sponsors, and ethics committees might improve evaluation and implementation of studies involving invasive nontherapeutic procedures. We conclude by urging more demanding scientific standards for the rationale, design, and reporting of burdensome, nontherapeutic research procedures-particularly where they involve risk of serious complications.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Comment in
-
Tissue Acquisition in Clinical Trials-Essential for Progress.J Natl Cancer Inst. 2017 Apr 1;109(4):djx003. doi: 10.1093/jnci/djx003. J Natl Cancer Inst. 2017. PMID: 28376161 Free PMC article. No abstract available.
References
-
- Goulart BH, Clark JW, Pien HH, et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007;13(22 Pt 1):6719–6726. - PubMed
-
- Wong HH, Barton C, Acton G, et al. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience. Eur J Cancer. 2016;66:9–16. - PubMed
-
- U.S. Food and Drug Administration. Hematology/oncology (cancer) approvals and safety notifications. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm. Accessed June 17, 2016.
-
- Yap TA, Sandhu SK, Workman P, et al. Envisioning the future of early anticancer drug development. Nat Rev Cancer. 2010;107:514–523. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
